Related Experiment Video

Updated: Apr 26, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and

Yuling Xi1, Ming Chen1, Xinmin Liu1

  • 1First Affiliated Hospital of Xinxiang Medical University, Xinxiang, People's Republic of China.

Oncotargets and Therapy
|July 23, 2014
PubMed

Insights

CP-673451, a platelet-derived growth factor receptor (PDGFR) kinase inhibitor, shows promise for non-small-cell lung cancer (NSCLC) therapy. It effectively suppressed tumor growth, viability, and metastasis in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer remains a leading cause of cancer mortality globally, with limited therapeutic advances improving patient survival.
  • Platelet-derived growth factor receptors (PDGFRs) and their ligands are implicated in cancer cell survival and motility.
  • Targeting PDGFR signaling presents a potential therapeutic strategy for lung cancer.

Purpose of the Study:

  • To investigate the anticancer effects of CP-673451, a selective PDGFR kinase inhibitor, in non-small-cell lung cancer (NSCLC).
  • To evaluate the impact of CP-673451 on NSCLC cell viability, apoptosis, migration, and invasion.
  • To assess the efficacy of CP-673451 in suppressing NSCLC tumor growth in vivo.

Main Methods:

  • Utilized NSCLC cell lines to assess the effects of CP-673451 on cellular processes.
  • Investigated the downstream signaling pathways affected by PDGFR inhibition.
  • Conducted in vivo studies using NSCLC tumor models to evaluate therapeutic efficacy.

Main Results:

  • CP-673451 demonstrated significant suppression of NSCLC cell viability.
  • The compound effectively induced apoptosis and inhibited cell migration and invasion in NSCLC cells.
  • CP-673451 treatment resulted in the suppression of NSCLC tumor growth in vivo.

Conclusions:

  • CP-673451 exhibits potent anticancer activities against NSCLC by inhibiting PDGFR signaling.
  • The findings suggest that CP-673451 is a promising therapeutic candidate for NSCLC treatment.
  • Targeting PDGFR kinase with CP-673451 warrants further clinical investigation for NSCLC.
Keywords:
CP-673451lung cancermigrationplatelet-derived growth factor receptors (PDGFRs)proliferation

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

9.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
688